早期直肠癌器官保留的研究进展

doi:10.16139/j.1007-9610.2024.03.05

摘要/Abstract

摘要：

探讨早期直肠癌器官保留策略的研究进展。尽管全直肠系膜切除术（TME）是标准治疗方法，但由于其可能导致生活质量下降，越来越多的关注转向器官保留策略。讨论早期直肠癌的精确分期方法，并针对cT1N0M0和cT2N0M0病人提出具体的器官保留方案。另外，对于错配修复缺陷(dMMR)/高度微卫星不稳定(MSI-H)病人，免疫疗法显示出巨大的潜力。总结当前研究成果，为临床医师在治疗早期直肠癌时提供有关器官保留的指导建议。

关键词: 早期直肠癌, 器官保留, 观察等待策略, 全程新辅助治疗

Abstract:

This review explored recent advancements in organ preservation strategies for early rectal cancer. Although total mesorectal excision (TME) remains the standard treatment, there is a growing interest in organ preservation approaches due to the potential decline in quality of life associated with TME. We discussed precise staging methods for early rectal cancer and proposed specific organ preservation protocols for cT1N0M0 and cT2N0M0 patients. Additionally, immunotherapy has shown significant potential for patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) status. This review summarized current research findings and provided guidance for clinicians on organ preservation options when treating early rectal cancer.

Key words: Early rectal cancer, Organ preservation, Watch-and-wait (W&W) strategy, Total neoadjuvant therapy(TNT)

中图分类号:

R735.37

宋子甲, 赵任. 早期直肠癌器官保留的研究进展[J]. 外科理论与实践, 2024, 29(03): 211-216.

SONG Zijia, ZHAO Ren. Research progress in organ preservation strategies for early rectal cancer[J]. Journal of Surgery Concepts & Practice, 2024, 29(03): 211-216.

参考文献 55

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2]	PATEL S A, CHEN Y H, HORNICK J L, et al. Early-stage rectal cancer: clinical and pathologic prognostic markers of time to local recurrence and overall survival after resection[J]. Dis Colon Rectum, 2014, 57(4):449-459. doi: 10.1097/DCR.0b013e3182a70709 pmid: 24608301
[3]	STORNES T, WIBE A, NESBAKKEN A, et al. National early rectal cancer treatment revisited[J]. Dis Colon Rectum, 2016, 59(7):623-629. doi: 10.1097/DCR.0000000000000591 pmid: 27270514
[4]	GARFINKLE R, BOUTROS M. Low anterior resection syndrome: predisposing factors and treatment[J]. Surg Oncol, 2022, 43:101691.
[5]	KEANE C, WELLS C, O'GRADY G, et al. Defining low anterior resection syndrome: a systematic review of the literature[J]. Colorectal Dis, 2017, 19(8):713-722. doi: 10.1111/codi.13767 pmid: 28612460
[6]	BATTERSBY N J, JUUL T, CHRISTENSEN P, et al. Predicting the risk of bowel-related quality-of-life impairment after restorative resection for rectal cancer: a multicenter cross-sectional study[J]. Dis Colon Rectum, 2016, 59(4):270-280. doi: 10.1097/DCR.0000000000000552 pmid: 26953985
[7]	YAMADA M, SAITO Y, SAKAMOTO T, et al. Endoscopic predictors of deep submucosal invasion in colorectal laterally spreading tumors[J]. Endoscopy, 2016, 48(5):456-464. doi: 10.1055/s-0042-100453 pmid: 26919264
[8]	D'AMICO F, AMATO A, IANNONE A, et al. Risk of covert submucosal cancer in patients with granular mixed laterally spreading tumors[J]. Clin Gastroenterol Hepatol, 2021, 19(7):1395-1401.
[9]	BACKES Y, MOSS A, REITSMA J B, et al. Narrow band imaging, magnifying chromoendoscopy, and gross morphological features for the optical diagnosis of T1 colorectal cancer and deep submucosal invasion: a systematic review and meta-analysis[J]. Am J Gastroenterol, 2017, 112(1):54-64. doi: 10.1038/ajg.2016.403 pmid: 27644737
[10]	ZHENG L J, HUANG X X, LU Z Z, et al. A diagnostic test: diagnostic value of gastrointestinal endoscopy narrow-band imaging (NBI) for colorectal laterally spreading tumor (LST) and submucosal invasion[J]. Transl Cancer Res, 2022, 11(12):4389-4396.
[11]	SAITO S, TAJIRI H, IKEGAMI M. Endoscopic features of submucosal deeply invasive colorectal cancer with NBI characteristics : S Saito et al. Endoscopic images of early colorectal cancer[J]. Clin J Gastroenterol, 2015, 8(6):353-359. doi: 10.1007/s12328-015-0616-5 pmid: 26661443
[12]	SANO Y, TANAKA S, KUDO S E, et al. Narrow-band imaging (NBI) magnifying endoscopic classification of colorectal tumors proposed by the Japan NBI Expert Team[J]. Dig Endosc, 2016, 28(5):526-533. doi: 10.1111/den.12644 pmid: 26927367
[13]	GLYNNE-JONES R, WYRWICZ L, TIRET E, et al. Rectal cancer:ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4):iv22-iv40.
[14]	DETERING R, VAN OOSTENDORP S E, MEYER V M, et al. MRI cT1-2 rectal cancer staging accuracy: a population-based study[J]. Br J Surg, 2020, 107(10):1372-1382.
[15]	LUGLIO G, PAGANO G, TROPEANO F P, et al. Endorectal ultrasonography and pelvic magnetic resonance imaging show similar diagnostic accuracy in local staging of rectal cancer: an update systematic review and meta-analysis[J]. Diagnostics (Basel), 2021, 12(1):5.
[16]	ROSéN R, NILSSON E, RAHMAN M, et al. Accuracy of MRI in early rectal cancer: national cohort study[J]. Br J Surg, 2022, 109(7):570-572. doi: 10.1093/bjs/znac059 pmid: 35277966
[17]	GORMLY K. Rectal MRI: the importance of high resolution T2 technique[J]. Abdom Radiol (NY), 2021, 46(9):4090-4095. doi: 10.1007/s00261-021-03047-2 pmid: 33881553
[18]	HOPE T A, KASSAM Z, LOENING A, et al. The use of PET/MRI for imaging rectal cancer[J]. Abdom Radiol (NY), 2019, 44(11):3559-3568. doi: 10.1007/s00261-019-02089-x pmid: 31201431
[19]	ROSENKRANTZ A B, FRIEDMAN K, CHANDARANA H, et al. Current status of hybrid PET/MRI in oncologic imaging[J]. Am J Roentgenol, 2016, 206(1):162-172. doi: 10.2214/AJR.15.14968 pmid: 26491894
[20]	KIM D J, KIM J H, RYU Y H, et al. Nodal staging of rectal cancer: high-resolution pelvic MRI versus ¹⁸F-FDGPET/CT[J]. J Comput Assist Tomogr, 2011, 35(5):531-534.
[21]	PATEL R K, SAYERS A E, KUMAR P, et al. The role of endorectal ultrasound and magnetic resonance imaging in the management of early rectal lesions in a tertiary center[J]. Clin Colorectal Cancer, 2014, 13(4):245-250.
[22]	HASHIGUCHI Y, MURO K, SAITO Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer[J]. Int J Clin Oncol, 2020, 25(1):1-42. doi: 10.1007/s10147-019-01485-z pmid: 31203527
[23]	SMITS L J H, VAN LIESHOUT A S, GRÜTER A A J, et al. Multidisciplinary management of early rectal cancer - the role of surgical local excision in current and future clinical practice[J]. Surg Oncol, 2022, 40:101687.
[24]	MIYACHI H, KUDO S E, ICHIMASA K, et al. Management of T1 colorectal cancers after endoscopic treatment based on the risk stratification of lymph node metastasis[J]. J Gastroenterol Hepatol, 2016, 31(6):1126-1132.
[25]	OKA S, TANAKA S, NAKADOI K, et al. Risk analysis of submucosal invasive rectal carcinomas for lymph node metastasis to expand indication criteria for endoscopic resection[J]. Dig Endosc,2013,25(Suppl 2):21-25.
[26]	YASUE C, CHINO A, TAKAMATSU M, et al. Pathological risk factors and predictive endoscopic factors for lymph node metastasis of T1 colorectal cancer: a single-center study of 846 lesions[J]. J Gastroenterol, 2019, 54(8):708-717. doi: 10.1007/s00535-019-01564-y pmid: 30810812
[27]	FERLITSCH M, MOSS A, HASSAN C, et al. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline[J]. Endoscopy, 2017, 49(3):270-297. doi: 10.1055/s-0043-102569 pmid: 28212588
[28]	BENSON A B, VENOOK A P, AL-HAWARY M M, et al. Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(10):1139-1167.
[29]	LI Y, QIU X, SHI W, et al. Adjuvant chemoradiotherapy versus radical surgery after transanal endoscopic microsurgery for intermediate pathological risk early rectal cancer: a single-center experience with long-term surveillance[J]. Surgery, 2022, 171(4):882-889.
[30]	CUTTING J E, HALLAM S E, THOMAS M G, et al. A systematic review of local excision followed by adjuvant therapy in early rectal cancer: are pT1 tumours the limit?[J]. Colorectal Dis, 2018, 20(10):854-863. doi: 10.1111/codi.14340 pmid: 29992729
[31]	VAN OOSTENDORP S E, SMITS L J H, VROOM Y, et al. Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment[J]. Br J Surg, 2020, 107(13):1719-1730.
[32]	DHADDA A, SUN MYINT A, THAMPHYA B, et al. A multi-centre analysis of adjuvant contact X-ray brachytherapy (CXB) in rectal cancer patients treated with local excision - preliminary results of the CONTEM1 study[J]. Radiother Oncol, 2021, 162:195-201. doi: 10.1016/j.radonc.2021.07.021 pmid: 34329654
[33]	BORSTLAP W A, TANIS P J, KOEDAM T W, et al. A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer[J]. BMC Cancer, 2016, 16:513.
[34]	GARCIA-AGUILAR J, RENFRO L A, CHOW O S, et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial[J]. Lancet Oncol, 2015, 16(15):1537-1546.
[35]	HABR-GAMA A, SÃO JULIÃO G P, FERNANDEZ L M, et al. Achieving a complete clinical response after neoadjuvant chemoradiation that does not require surgical resection: it may take longer than you think![J]. Dis Colon Rectum, 2019, 62(7):802-808.
[36]	KENNECKE H F, O'CALLAGHAN C J, LOREE J M, et al. Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: the phase Ⅱ NEO trial (CCTG CO.28) primary end point results[J]. J Clin Oncol, 2023, 41(2):233-242.
[37]	RULLIER E, ROUANET P, TUECH J J, et al. Organ preservation for rectal cancer (GRECCAR 2): a prospective, randomised, open-label, multicentre, phase 3 trial[J]. Lancet, 2017, 390(10093):469-479. doi: S0140-6736(17)31056-5 pmid: 28601342
[38]	BACH S P, GILBERT A, BROCK K, et al. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study[J]. Lancet Gastroenterol Hepatol, 2021, 6(2):92-105.
[39]	CERCEK A, ROXBURGH C S D, STROMBOM P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer[J]. JAMA Oncol, 2018, 4(6):e180071.
[40]	HABR-GAMA A, SABBAGA J, GAMA-RODRIGUES J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?[J]. Dis Colon Rectum, 2013, 56(10):1109-1117.
[41]	HABR-GAMA A, SÃO JULIÃO G P, VAILATI B B, et al. Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy[J]. Ann Surg, 2019, 269(1):102-107.
[42]	FOKAS E, ALLGÄUER M, POLAT B, et al. Randomized phase Ⅱ trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12[J]. J Clin Oncol, 2019, 37(34):3212-3122.
[43]	GARCIA-AGUILAR J, PATIL S, GOLLUB M J, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy[J]. J Clin Oncol, 2022, 40(23):2546-2556.
[44]	SERRA-ARACIL X, PERICAY C, BADIA-CLOSA J, et al. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase Ⅲ trial (the TAU-TEM study)[J]. Ann Oncol, 2023,34(1):78-90.
[45]	EMILE S H, KHAN S M, GAROUFALIA Z, et al. When is a diverting stoma indicated after low anterior resection? A meta-analysis of randomized trials and meta-regression of the risk factors of leakage and complications in non-diverted patients[J]. J Gastrointest Surg, 2022, 26(11):2368-2379. doi: 10.1007/s11605-022-05427-5 pmid: 35915378
[46]	VAN DER VALK M J M, HILLING D E, BASTIAANNET E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study[J]. Lancet, 2018, 391(10139):2537-2545.
[47]	CHADI S A, MALCOMSON L, ENSOR J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis[J]. Lancet Gastroenterol Hepatol, 2018, 3(12):825-836.
[48]	FERNANDEZ L M, FIGUEIREDO N L, HABR-GAMA A, et al. Salvage surgery with organ preservation for patients with local regrowth after watch and wait: is it still possible?[J]. Dis Colon Rectum, 2020, 63(8):1053-1062. doi: 10.1097/DCR.0000000000001707 pmid: 32692070
[49]	ANDRé T, SHIU K K, KIM T W, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer[J]. N Engl J Med, 2020, 383(23):2207-2218.
[50]	LENZ H J, VAN CUTSEM E, LUISA LIMON M, et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase Ⅱ checkmate 142 study[J]. J Clin Oncol, 2022, 40(2):161-170.
[51]	CHALABI M, VERSCHOOR Y L, TAN P B, et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer[J]. N Engl J Med, 2024, 390(21):1949-1958.
[52]	CERCEK A, LUMISH M, SINOPOLI J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer[J]. N Engl J Med, 2022, 386(25):2363-2376.
[53]	VEEN T, KANANI A, LEA D, et al. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer[J]. Cancer Immunol Immunother, 2023, 72(10):3135-3147. doi: 10.1007/s00262-023-03480-w pmid: 37528319
[54]	CHAKRABARTI S, GREWAL U S, VORA K B, et al. Outcome of patients with early-stage mismatch repair deficient colorectal cancer receiving neoadjuvant immunotherapy: a systematic review[J]. JCO Precis Oncol, 2023, 7:e2300182.
[55]	GANI C, GANI N, ZSCHAECK S, et al. Organ preservation in rectal cancer: the patients' perspective[J]. Front Oncol, 2019, 9:318. doi: 10.3389/fonc.2019.00318 pmid: 31134146